Almac, Pfizer reveal steps to slash gene therapy labeling times 12-Feb-2020 By Nick Taylor Almac outlines work with Pfizer to quickly get patient-specific gene therapies to DMD patients.
GSK's pullback from low-margin contract manufacturing drags on results 10-Feb-2020 By Nick Taylor GSK blames retreat from low-margin contract manufacturing for flat fourth quarter performance of consumer health unit.
Novartis, Gilead in joint financing of personalized medicine platform 06-Feb-2020 By Vassia Barba Vineti’s latest financing round sees Novartis and Gilead join forces to invest in technology platform that enables scale-up of CAR Ts and allogeneic cell therapies.
Novartis tips complex manufacturing to insulate Sandostatin from generics 03-Feb-2020 By Nick Taylor Novartis expects generics to slowly erode sales of Sandostatin given production challenges.
Pfizer's CDMO unit drives growth at hospital business 03-Feb-2020 By Nick Taylor Pfizer attributes performance of contract manufacturing unit as driver of growth at hospital business.
Bellicum offloads cell therapy plant in switch to outsourced production 28-Jan-2020 By Nick Taylor Bellicum sells cell therapy manufacturing plant to MD Anderson Cancer Center, strikes master service agreement.
New CDMO plans $1.1bn cell and gene therapy plant 27-Jan-2020 By Nick Taylor A newly founded CDMO has outlined plans to invest $1.1bn to become the world’s biggest cell and gene therapy service provider.
Lilly to build $470m North Carolina facility, trumpets tax reform 23-Jan-2020 By Ben Hargreaves Lilly will begin construction of a parenteral products-focused facility this year, suggesting that 462 new jobs will be created.
Merck looks to CMOs to help ease vaccine supply bottleneck 20-Jan-2020 By Nick Taylor Merck enlists CMOs to help increase Gardasil manufacturing capacity in response to rising demand.
PharmaMar to supply Jazz with drug product under $1bn deal 16-Jan-2020 By Nick Taylor PharmaMar set to supply Jazz Pharmaceuticals with cancer drug from two sites under terms of $1bn deal.
Sterling expects further HPAPI demand, looks for buy-out opportunities 15-Jan-2020 By Vassia Barba Sterling continues expansion and lines up further acquisitions, as the HPAPI market continues to see increasing demand, a company executive says.
FDA places Innate cancer trial on partial clinical hold over CMO issue 14-Jan-2020 By Nick Taylor The US FDA puts Innate Pharma trial on partial clinical hold after learning of CMO problems.
3M set to sell biopharma-focused CDMO for $650m 23-Dec-2019 By Nick Taylor 3M agrees to sell drug delivery contract service unit to investment group Altaris Capital Partners.
Avid frames Halozyme setback as potential positive for CDMO business 19-Dec-2019 By Nick Taylor Avid Bioservices sees potential upside to clinical development setback at big customer Halozyme.
Sanofi to 'optimize' CMOs to drive down spending 18-Dec-2019 By Nick Taylor Sanofi plans “optimization of CMOs and suppliers” as new CEO targets €2bn in savings by 2022.
